Other Income & Expense
Derivative Gain (Loss) Excluded from Effectiveness
AbbVie Derivative Gain (Loss) Excluded from Effectiveness increased by 1.5% to -$645.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.9%, from -$627.00M to -$645.00M. Over 4 years (FY 2021 to FY 2025), Derivative Gain (Loss) Excluded from Effectiveness shows a downward trend with a 2.5% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
First reportedQ1 2013
Last reportedQ1 2026May 8, 2026
Metric ID:
abbv_derivative_gain_loss_excluded_from_effectivenessHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$606.00M | -$585.00M | -$571.00M | -$539.00M | -$532.00M | -$497.00M | -$476.00M | -$454.00M | -$454.00M | -$398.00M | -$378.00M | -$453.00M | -$506.00M | -$591.00M | -$610.00M | -$627.00M | -$678.00M | -$667.00M | -$655.00M | -$645.00M |
| QoQ Change | — | +3.5% | +2.4% | +5.6% | +1.3% | +6.6% | +4.2% | +4.6% | +0.0% | +12.3% | +5.0% | -19.8% | -11.7% | -16.8% | -3.2% | -2.8% | -8.1% | +1.6% | +1.8% | +1.5% |
| YoY Change | — | — | — | — | +12.2% | +15.0% | +16.6% | +15.8% | +14.7% | +19.9% | +20.6% | +0.2% | -11.5% | -48.5% | -61.4% | -38.4% | -34.0% | -12.9% | -7.4% | -2.9% |
Range-$678.00M – -$378.00M
CAGR+1.3%
Avg YoY Growth-6.4%
Median YoY Growth-1.3%
Current Streak3 quarters growth
Derivative Gain (Loss) Excluded from Effectiveness at Other Companies
Frequently Asked Questions
- What is AbbVie's derivative gain (loss) excluded from effectiveness?
- AbbVie (ABBV) reported derivative gain (loss) excluded from effectiveness of -$645.00M in Q1 2026.
- How has AbbVie's derivative gain (loss) excluded from effectiveness changed year-over-year?
- AbbVie's derivative gain (loss) excluded from effectiveness decreased by 2.9% year-over-year, from -$627.00M to -$645.00M.
- What is the long-term trend for AbbVie's derivative gain (loss) excluded from effectiveness?
- Over 4 years (2021 to 2025), AbbVie's derivative gain (loss) excluded from effectiveness has grown at a 2.5% compound annual growth rate (CAGR), from -$2.38B to -$2.63B.